Skip to main content
OpenTrials
Completed

NCT Number: NCT06368310

FIH Clinical Investigation of Graphene Electrodes for Brain Mapping

The goal of this clinical investigation of a medical device is to test the safety of graphene based electrodes when used during surgery for resection of brain tumors. The main questions that it aims to answer are:

* To understand the safety of the Graphene Cortical Interface when used during brain tumor surgery (primary objective); * To assess the quality of the brain signals recorded with the Graphene Cortical Interface, their ability to stimulate the brain, how stable their function is over the duration of an operation, and their suitability for use in the operating theatre (secondary objectives).

Participants will undergo tumor surgery as usual with the study electrodes being tested alongside a standard monitoring system. If they are awake for part of their surgery they may be asked to complete specific tasks such as naming objects from a list modified for the study, to evaluate the capability to decode brain signals (exploratory objective). They will be monitored subsequently for any complications including undergoing an additional MRI scan 6 weeks after their surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Manchester Centre for Clinical Neurosciences, Northern Care Alliance NHS Foundation Trust

Salford, Greater Manchester, M6 8HD, United Kingdom

About this study

During surgical operations within the brain such as the removal of a tumor, electrodes are commonly used to map specific brain functions or monitor brain activity. These are most commonly flexible plastic devices with embedded metallic contacts that allow electrical activity in the brain to be detected and measured. They may also be used to stimulate precise areas of the brain to either trigger or block a response such as the contraction of a muscle. This allows the surgeon to define which regions of the brain are involved in controlling critical functions such as movement or speech so that these areas can be protected during the operation.

There remain limitations with the design and physical characteristics of commercially available electrodes for use during brain operations. These include the limited ability of conventional materials to fold over the complex shape of the brain and the need to use comparatively large metallic contacts to detect the tiny electrical signals. This study will be the first to introduce a new generation of electrodes which have been designed to overcome these limitations. They are extremely thin and flexible allowing them to follow the surface of the brain and to be used in locations within and around the brain for which the standard electrodes are unsuitable. The contact surfaces that detect electrical activity and enable and stimulate the brain have been replaced with graphene which is a novel carbon-based material. The use of graphene allows electrodes to be made that are more sensitive to the tiny electrical signals of the brain. This means that they can be much smaller and closer together providing increased detail in the recording and potentially enabling signals to be detected that would previously have required such long recordings that they could not be used to guide decision making during surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Solitary supratentorial tumor radiologically consistent with glioma (intrinsic primary brain tumor) on standard diagnostic MRI;
  • Planned for surgery under awake conditions or under general anesthesia with intra-operative electrocorticography (ECoG);
  • English as first language for those subjects with tumors associated with language areas;
  • Karnofsky performance score > 70 and World Health Organization (WHO) performance status score ≤ 1;
  • Willing and able to understand and provide informed consent for participating in the study.

Exclusion criteria

  • Contraindications to magnetic resonance imaging (e.g., incompatible implanted devices);
  • Previous cranial surgery or radiotherapy;
  • Subjects expected to undergo craniotomy of less than 5 cm in maximum diameter (bone to bone)
  • Known extracranial malignant neoplasm;
  • Pregnant or lactating women;
  • Renal impairment sufficient to limit Gadolinium administration (EGFR <60 ml/min)
  • For those subjects with tumors associated with language areas, any contraindication which could preclude them from performing the whole awake intra operative tasks at the discretion of the Investigator (e.g., language function not suitable for monitoring tasks)

Treatment and study plan

INBRAIN Graphene Cortical Interface

Device

Study device to be evaluated intra-operatively alongside standard of care neurophysiological monitoring.

Primary outcomes

  1. To evaluate the preliminary safety of the investigational device for its intended use

    Time frame: Through study completion, an average of 3 months

    All adverse events (including, but not limited to, adverse device events)

Secondary outcomes

  1. Assess the ability of the device to record signals from the brain

    Time frame: During surgical procedure

    Performance of detecting signals from the brain by sensing of electrical brain activity

  2. Evaluate the ability of the device to provide functional stimulation of the brain

    Time frame: During surgical procedure

    Performance of functional stimulation of the brain by inducing evoked motor responses measured as peripheral muscle electromyography (EMG)

  3. Assess stability of sensing and stimulating electrodes

    Time frame: During surgical procedure

    Stability of electrodes by evaluation of impedance measurements over time

  4. Evaluate device usability - an assessment by questionnaire of the operating surgeon's impression of the suitability of the device for sensing and stimulation during brain tumor surgery

    Time frame: During surgical procedure

    Study specific questionnaire to be completed by the operating surgeon including ease of handling, positioning and removal of the electrode. The study specific 'Device Usability' tool scores outcomes on a scale of 1-4 where 4 represents a favourable feature.

Other outcomes

  1. Assess the quality of the recorded somatosensory evoked potentials (SEPs) - sensing part A (exploratory)

    Time frame: During surgical procedure

    Assessing the quality of recorded brain activity by measuring signal to noise ratio (SNR) during stimulation of a peripheral nerve

  2. Assess the quality of the recorded baseline brain activity - sensing part B (exploratory)

    Time frame: During surgical procedure

    Assessing the quality of recorded brain activity at rest (or under anaesthesia) evaluated as the power spectral density (PSD)

  3. Assess the ability of detecting brain evoked responses during stimulation of the brain (exploratory)

    Time frame: During surgical procedure

    Preliminary assessment of the ability of the device to detect changes in brain activity evoked in response to stimulation of distant but connected brain regions

  4. Evaluate decoding capability from data recorded during language task (exploratory)

    Time frame: During surgical procedure

    Preliminary evaluation of the ability to detect changes in brain activity that correspond to word or sound generation as the participant completes a standardized object naming task (quantified by classification accuracy)

  5. Evaluate signal characteristics of tumour infiltrated brain regions (exploratory)

    Time frame: During surgical procedure

    Preliminary evaluation of changes in the pattern of brain activity in healthy brain versus that infiltrated by tumour quantified by changes in the power spectral density (PSD)

Sponsors and collaborators

Lead sponsor

University of Manchester

Other

Collaborators

  • European Commission
  • Inbrain Neuroelectronics
  • Northern Care Alliance NHS Foundation Trust

Registry information

Official study title

First in Human (FIH) Clinical Investigation of Safety and Feasibility of a Novel Graphene Micro-electrocorticography Array for Brain Mapping in Neuro-oncology

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Apr 16, 2024
Registry last updated
Jun 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.